Known possible [[side effect]]s of AAS include:<ref name="pmid21443513">{{cite journal | vauthors = Turillazzi E, Perilli G, Di Paolo M, Neri M, Riezzo I, Fineschi V | title = Side effects of AAS abuse: an overview | journal = Mini Rev Med Chem | volume = 11 | issue = 5 | pages = 374–89 | year = 2011 | pmid = 21443513 | doi = | url = }}</ref><ref name="pmid17723870">{{cite journal | vauthors = Casavant MJ, Blake K, Griffith J, Yates A, Copley LM | title = Consequences of use of anabolic androgenic steroids | journal = Pediatr. Clin. North Am. | volume = 54 | issue = 4 | pages = 677–90, x | year = 2007 | pmid = 17723870 | doi = 10.1016/j.pcl.2007.04.001 | url = }}</ref><ref name="pmid24423981">{{cite journal | vauthors = Pope HG, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S | title = Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement | journal = Endocr. Rev. | volume = 35 | issue = 3 | pages = 341–75 | year = 2014 | pmid = 24423981 | pmc = 4026349 | doi = 10.1210/er.2013-1058 | url = }}</ref><ref name="pmid19028512">{{cite journal | vauthors = Fragkaki AG, Angelis YS, Koupparis M, Tsantili-Kakoulidou A, Kokotos G, Georgakopoulos C | title = Structural characteristics of anabolic androgenic steroids contributing to binding to the androgen receptor and to their anabolic and androgenic activities. Applied modifications in the steroidal structure | journal = Steroids | volume = 74 | issue = 2 | pages = 172–97 | year = 2009 | pmid = 19028512 | doi = 10.1016/j.steroids.2008.10.016 | url = }}</ref><ref name="pmid25805894">{{cite journal | vauthors = Nieschlag E, Vorona E | title = MECHANISMS IN ENDOCRINOLOGY: Medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions | journal = Eur. J. Endocrinol. | volume = 173 | issue = 2 | pages = R47–58 | year = 2015 | pmid = 25805894 | doi = 10.1530/EJE-15-0080 | url = }}</ref>

 


 
* [[Cutaneous condition|Dermatological]]/[[integumentary system|integumental]]: [[oily skin]], [[acne vulgaris]], [[acne conglobata]], [[seborrhea]], [[stretch mark]]s (due to rapid [[muscle hypertrophy|muscle enlargement]]), [[hypertrichosis]] (excessive hair growth), [[androgenic alopecia]] (pattern hair loss; scalp baldness), [[water retention (medicine)|fluid retention]]/[[edema]].

 
* [[Reproductive system disease|Reproductive]]/[[endocrine disease|endocrine]]: [[libido]] changes, reversible [[infertility]], [[hypogonadotropic hypogonadism]].

 
* Male-specific: [[spontaneous erection]]s, [[nocturnal emission]]s, [[priapism]], [[erectile dysfunction]], [[gynecomastia]] (mostly only with [[aromatase|aromatizable]] and hence [[estrogen]]ic AAS), [[oligospermia]]/[[azoospermia]], [[testicular atrophy]], [[intratesticular leiomyosarcoma]], [[prostate hypertrophy]], [[prostate cancer]].

 
* Female-specific: [[masculinization]], irreversible [[voice deepening]], [[hirsutism]] (excessive facial/body hair growth), [[menstrual disturbances]] (e.g., [[anovulation]], [[oligomenorrhea]], [[amenorrhea]], [[dysmenorrhea]]), [[clitoral enlargement]], [[breast atrophy]], [[uterine atrophy]], [[teratogenicity]] (in female [[fetus]]es).

 
* Child-specific: premature [[epiphyseal closure]] and associated [[short stature]], [[precocious puberty]] in boys, [[delayed puberty]] and [[contrasexual precocity]] in girls.

 
* [[Emotional and behavioral disorders|Psychiatric]]/[[Neurological disorder|neurological]]: [[mood swing]]s, [[irritability]], [[aggression]], [[violence|violent behavior]], [[impulsivity]]/[[recklessness (psychology)|recklessness]], [[hypomania]]/[[mania]], [[euphoria]], [[depression (mood)|depression]], [[anxiety]], [[dysphoria]], [[suicidality]], [[delusion]]s, [[psychosis]], [[drug withdrawal|withdrawal]], [[drug dependence|dependence]], [[neurotoxicity]], [[cognitive impairment]].<ref name="pmid16000671">{{cite journal | vauthors = Hall RC, Hall RC, Chapman MJ | title = Psychiatric complications of anabolic steroid abuse | journal = Psychosomatics | volume = 46 | issue = 4 | pages = 285–90 | year = 2005 | pmid = 16000671 | doi = 10.1176/appi.psy.46.4.285 | url = }}</ref><ref name="pmid15984895">{{cite journal | vauthors = Trenton AJ, Currier GW | title = Behavioural manifestations of anabolic steroid use | journal = CNS Drugs | volume = 19 | issue = 7 | pages = 571–95 | year = 2005 | pmid = 15984895 | doi = | url = }}</ref>

 
* [[Musculoskeletal disorder|Musculoskeletal]]: [[muscle hypertrophy]], [[strain (injury)|muscle strain]]s, [[tendon rupture]]s, [[rhabdomyolysis]].

 
* [[Cardiovascular disease|Cardiovascular]]: [[dyslipidemia]] (e.g., increased {{abbrlink|LDL|low-density lipoprotein}} levels, decreased {{abbrlink|HDL|high-density lipoprotein}} levels, reduced {{abbrlink|apo-A1|apolipoprotein A1}} levels), [[atherosclerosis]], [[hypertension]], [[left ventricular hypertrophy]], [[cardiomyopathy]], [[myocardial hypertrophy]], [[polycythemia]]/[[erythrocytosis]], [[arrhythmia]]s, [[thrombosis]] (e.g., [[embolism]], [[stroke]]), [[myocardial infarction]], [[sudden cardiac death|sudden death]].<ref name="pmid20020375">{{cite journal | vauthors = Vanberg P, Atar D | title = Androgenic anabolic steroid abuse and the cardiovascular system | journal = Handb Exp Pharmacol | volume = | issue = 195 | pages = 411–57 | year = 2010 | pmid = 20020375 | doi = 10.1007/978-3-540-79088-4_18 | url = }}</ref><ref name="pmid20816133">{{cite journal | vauthors = Achar S, Rostamian A, Narayan SM | title = Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm | journal = Am. J. Cardiol. | volume = 106 | issue = 6 | pages = 893–901 | year = 2010 | pmid = 20816133 | pmc = 4111565 | doi = 10.1016/j.amjcard.2010.05.013 | url = }}</ref>

 
* [[Liver disease|Hepatic]]: elevated [[liver function test]]s ({{abbrlink|AST|aspartate aminotransferase}}, {{abbrlink|ALT|alanine aminotransferase}}, [[bilirubin]], {{abbrlink|LDH|lactic dehydrogenase}}, {{abbrlink|ALP|alkaline phosphatase}}), [[hepatotoxicity]], [[jaundice]], [[hepatic steatosis]], [[hepatocellular adenoma]], [[hepatocellular carcinoma]], [[cholestasis]], [[peliosis hepatis]]; all mostly or exclusively with 17α-alkylated AAS.<ref name="pmid28379599">{{cite journal | vauthors = Solimini R, Rotolo MC, Mastrobattista L, Mortali C, Minutillo A, Pichini S, Pacifici R, Palmi I | title = Hepatotoxicity associated with illicit use of anabolic androgenic steroids in doping | journal = Eur Rev Med Pharmacol Sci | volume = 21 | issue = 1 Suppl | pages = 7–16 | year = 2017 | pmid = 28379599 | doi = | url = }}</ref>

 
* [[Renal disease|Renal]]: [[renal hypertrophy]], [[nephropathy]], [[acute renal failure]] (secondary to rhabdomyolysis), [[focal segmental glomerulosclerosis]], [[renal cell carcinoma]].

 
* Others: [[glucose intolerance]], [[insulin resistance]], [[immune dysfunction]].<ref name="pmid21443507">{{cite journal | vauthors = Brenu EW, McNaughton L, Marshall-Gradisnik SM | title = Is there a potential immune dysfunction with anabolic androgenic steroid use?: A review | journal = Mini Rev Med Chem | volume = 11 | issue = 5 | pages = 438–45 | year = 2011 | pmid = 21443507 | doi = | url = }}</ref>

 

